Chemistry:YM-348: Difference between revisions

From HandWiki
(link)
 
(No difference)

Latest revision as of 20:16, 17 December 2022

Short description: Chemical compound
YM-348
YM-348.svg
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
Chemical and physical data
FormulaC14H17N3O
Molar mass243.310 g·mol−1
3D model (JSmol)
  (verify)

YM-348 is an indazole derivative drug which acts as a potent and selective 5-HT2C receptor agonist, with an EC50 of 1nM and 15x selectivity over 5-HT2A, although it only has moderate selectivity of 3x over the closely related 5-HT2B receptor.[1][2] It has thermogenic and anorectic effects in animal studies, making it potentially useful for the treatment of obesity.[3][4][5][6]

See also

References

  1. "Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist". European Journal of Pharmacology 483 (1): 37–43. January 2004. doi:10.1016/j.ejphar.2003.10.004. PMID 14709324. 
  2. "Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists". Bioorganic & Medicinal Chemistry 16 (4): 1966–82. February 2008. doi:10.1016/j.bmc.2007.10.100. PMID 18035544. 
  3. "Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats". Brain Research 1011 (2): 221–7. June 2004. doi:10.1016/j.brainres.2004.03.032. PMID 15157808. 
  4. "The potential use of selective 5-HT2C agonists in treating obesity". Expert Opinion on Investigational Drugs 15 (3): 257–66. March 2006. doi:10.1517/13543784.15.3.257. PMID 16503763. 
  5. "5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents". Journal of Medicinal Chemistry 49 (14): 4023–34. July 2006. doi:10.1021/jm058240i. PMID 16821762. 
  6. "Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases". Current Opinion in Drug Discovery & Development 11 (4): 438–45. July 2008. PMID 18600561.